Kaiser, Rainer W. J. http://orcid.org/0000-0003-1750-3395
Ignarski, Michael http://orcid.org/0000-0001-6057-7694
Van Nostrand, Eric L.
Frese, Christian K.
Jain, Manaswita
Cukoski, Sadrija
Heinen, Heide
Schaechter, Melanie
Seufert, Lisa
Bunte, Konstantin
Frommolt, Peter
Keller, Patrick
Helm, Mark
Bohl, Katrin
Höhne, Martin
Schermer, Bernhard http://orcid.org/0000-0002-5194-9000
Benzing, Thomas
Höpker, Katja
Dieterich, Christoph
Yeo, Gene W.
Müller, Roman-Ulrich http://orcid.org/0000-0001-6910-0745
Fabretti, Francesca
Funding for this research was provided by:
Boehringer Ingelheim Fonds
Damon Runyon Cancer Research Foundation (DRG-2172-13)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (HG009530, U54HG007005)
Deutsche Forschungsgemeinschaft (HE3397/8-1, HE3397/13-2 and SPP1784, SCHE1562/6, BE2212 and KFO329)
Klaus Tschira Stiftung (CD)
U.S. Department of Health & Human Services | National Institutes of Health (HG007005 and NS075449)
Article History
Received: 3 January 2019
Accepted: 19 July 2019
First Online: 30 July 2019
Competing Interests
: ELVN is co-founder, member of the Board of Directors, on the SAB, equity holder, and paid consultant for Eclipse BioInnovations. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies.